While working as a Professor in MCB's Division of Immunology, Dr. Jim Allison developed the immunotherapy drug Yervoy (Ipilimumab), the first drug to improve overall survival for patients with advanced metastatic melanoma, the deadliest form of skin cancer. Yervoy was an informative feature story for the Association of University Technology Managers (AUTM) that describes both the research and the technology transfer process.
Postscript to Above Article:
Dr. Allison has also now left Memorial Sloan-Kettering Cancer Center in NYC and is now Professor and Chair of Immunology and Executive Director of Immunotherapy Platform at the Univ. of Texas M. D. Anderson Cancer Center in Houston, TX.